1. Home
  2. PCRX vs CCNE Comparison

PCRX vs CCNE Comparison

Compare PCRX & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • CCNE
  • Stock Information
  • Founded
  • PCRX 2006
  • CCNE 1865
  • Country
  • PCRX United States
  • CCNE United States
  • Employees
  • PCRX N/A
  • CCNE N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • CCNE Major Banks
  • Sector
  • PCRX Health Care
  • CCNE Finance
  • Exchange
  • PCRX Nasdaq
  • CCNE Nasdaq
  • Market Cap
  • PCRX 1.2B
  • CCNE 455.3M
  • IPO Year
  • PCRX 2011
  • CCNE N/A
  • Fundamental
  • Price
  • PCRX $23.31
  • CCNE $24.44
  • Analyst Decision
  • PCRX Buy
  • CCNE Hold
  • Analyst Count
  • PCRX 8
  • CCNE 1
  • Target Price
  • PCRX $28.38
  • CCNE $25.00
  • AVG Volume (30 Days)
  • PCRX 537.5K
  • CCNE 69.4K
  • Earning Date
  • PCRX 07-29-2025
  • CCNE 07-17-2025
  • Dividend Yield
  • PCRX N/A
  • CCNE 2.96%
  • EPS Growth
  • PCRX N/A
  • CCNE N/A
  • EPS
  • PCRX N/A
  • CCNE 2.34
  • Revenue
  • PCRX $702,772,000.00
  • CCNE $219,886,000.00
  • Revenue This Year
  • PCRX $7.54
  • CCNE $17.91
  • Revenue Next Year
  • PCRX $10.78
  • CCNE $27.71
  • P/E Ratio
  • PCRX N/A
  • CCNE $10.41
  • Revenue Growth
  • PCRX 3.08
  • CCNE 1.97
  • 52 Week Low
  • PCRX $11.16
  • CCNE $18.90
  • 52 Week High
  • PCRX $27.64
  • CCNE $29.29
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 37.20
  • CCNE 70.42
  • Support Level
  • PCRX $22.82
  • CCNE $23.94
  • Resistance Level
  • PCRX $23.83
  • CCNE $24.50
  • Average True Range (ATR)
  • PCRX 0.67
  • CCNE 0.48
  • MACD
  • PCRX -0.05
  • CCNE 0.21
  • Stochastic Oscillator
  • PCRX 20.73
  • CCNE 98.01

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.

Share on Social Networks: